Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
| Revenue (Most Recent Fiscal Year) | $100.33B |
| Net Income (Most Recent Fiscal Year) | $31.37B |
| PE Ratio (Current Year Earnings Estimate) | 11.23 |
| PE Ratio (Trailing 12 Months) | 6.07 |
| PEG Ratio (Long Term Growth Estimate) | 1.25 |
| Price to Sales Ratio (Trailing 12 Months) | 2.28 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.10 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 4.93 |
| Pre-Tax Margin (Trailing 12 Months) | 34.37% |
| Net Margin (Trailing 12 Months) | 31.25% |
| Return on Equity (Trailing 12 Months) | 37.53% |
| Return on Assets (Trailing 12 Months) | 18.08% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.11 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.31 |
| Inventory Turnover (Trailing 12 Months) | 3.04 |
| Book Value per Share (Most Recent Fiscal Quarter) | $17.09 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.23 |
| Earnings per Share (Most Recent Fiscal Year) | $6.58 |
| Diluted Earnings per Share (Trailing 12 Months) | $5.08 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 5.65B |
| Free Float | 5.64B |
| Market Capitalization | $212.26B |
| Average Volume (Last 20 Days) | 30.38M |
| Beta (Past 60 Months) | 0.63 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.05% |
| Percentage Held By Institutions (Latest 13F Reports) | 67.62% |
| Annual Dividend (Based on Last Quarter) | $1.64 |
| Dividend Yield (Based on Last Quarter) | 4.36% |